People · Operator
Named in public records as an officer, director or promoter · active 2018–2018 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| MEI Pharma, Inc. | — | Pharmaceuticals | Series C | $76.1M | $2.6B | 2018 |
Nicholas R. Glover at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Nicholas R. Glover on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| William D. Rueckert | 1 | 4 |
| Frederick W. Driscoll | 1 | 2 |
| Christine A. White | 1 | 2 |
| David M. Urso | 1 | 2 |
| Thomas C. Reynolds | 1 | 2 |
| Leah D. Cann | 1 | 1 |
| Daniel P. Gold | 1 | 1 |
| Brian G. Drazba | 1 | 1 |
| Kevan E. Clemens | 1 | 1 |
| Charles V. Baltic III | 1 | 1 |
| Thomas M. Zech | 1 | 1 |
| Robert D. Mass | 1 | 1 |
| Bryan M. Williams | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.